发明名称 |
uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin. |
摘要 |
The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine. |
申请公布号 |
BRPI0909227(A2) |
申请公布日期 |
2015.12.01 |
申请号 |
BR2009PI09227 |
申请日期 |
2009.03.23 |
申请人 |
ROCHE GLYCART AG |
发明人 |
CHARLES DUMONTET;CHRISTIAN KLEIN;FRANK HERTING;PABLO UMANA;THOMAS FRIESS |
分类号 |
A61K39/395;A61P35/00;C07K16/28 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|